Profile data is unavailable for this security.
About the company
Thiogenesis Therapeutics, Corp. is a Canada-based clinical-stage biopharmaceutical company. The Company is engaged in developing thiol-active therapeutic compounds, which are prodrugs used to treat unmet pediatric medical needs. The Company’s lead compound, TTI-0102, is a disulfide, made up of two thiols that lead to two independent cysteamine molecules. Cysteamine is a thiol that has been rigorously studied and tested. It is the active ingredient used in drugs to treat the lysosomal storage disease - (nephropathic) cystinosis. TTI-0102 has been developed to address the important obstacles facing thiol-based drugs, their short half-life, strong gastrointestinal (GI) side-effects and dosing limitations. As a prodrug, TTI-0102 is metabolized into cysteamine molecules after it is ingested. The metabolic process acts as a gating mechanism. TTI-0102’s initial applications are for mitochondrial disease, Rett syndrome and pediatric non-alcoholic steatohepatitis (NASH).
- Revenue in CAD (TTM)0.00
- Net income in CAD-4.71m
- Incorporated2018
- Employees--
- LocationThiogenesis Therapeutics Corp4 King Street West, Suite 401Toronto M5H 1B6CanadaCAN
- Phone+1 (647) 846-7766
- Websitehttps://www.thiogenesis.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AEterna Zentaris Inc. | 3.24m | -24.62m | 18.98m | 21.00 | -- | 0.4255 | -- | 5.86 | -20.28 | -20.28 | 2.67 | 14.57 | 0.0572 | 1.52 | 6.36 | -- | -43.46 | -26.24 | -50.57 | -30.34 | 90.69 | 83.68 | -760.32 | -300.31 | 5.93 | -- | 0.0177 | -- | -20.25 | -30.06 | 27.17 | -- | 16.12 | -- |
| Kane Biotech Inc | 165.60k | -4.94m | 19.12m | -- | -- | -- | -- | 115.44 | -0.0383 | -0.0399 | 0.0013 | -0.089 | 0.0294 | 0.085 | 1.25 | -- | -87.75 | -77.89 | -- | -- | 73.29 | 43.27 | -2,984.41 | -241.85 | 0.2957 | -2.88 | -- | -- | -94.42 | -20.26 | -17.29 | -- | -19.41 | -- |
| Briacell Therapeutics Corp | 0.00 | -8.18m | 25.83m | 5.00 | -- | -- | -- | -- | -0.5337 | -0.5337 | 0.00 | -0.5091 | 0.00 | -- | -- | -- | -33.97 | -59.37 | -43.50 | -63.11 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 24.35 | -- | -- | -- |
| Thiogenesis Therapeutics Corp | 0.00 | -4.71m | 30.94m | -- | -- | 5.79 | -- | -- | -0.1173 | -0.1173 | 0.00 | 0.1175 | 0.00 | -- | -- | -- | -85.31 | -- | -90.24 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- |
| MustGrow Biologics Corp | 4.71m | -665.06k | 36.75m | 0.00 | -- | 8.11 | -- | 7.80 | -0.0134 | -0.0134 | 0.0936 | 0.0912 | 0.7632 | -- | 45.31 | -- | -10.77 | -50.41 | -14.00 | -59.28 | -- | -- | -14.11 | -298.73 | -- | -- | 0.1393 | -- | 72,619.13 | 372.54 | 87.84 | -- | -- | -- |
| Microbix Biosystems Inc | 23.84m | 4.06m | 41.72m | 69.00 | 10.32 | 1.51 | 7.64 | 1.75 | 0.0296 | 0.0296 | 0.173 | 0.202 | 0.6703 | 1.67 | 6.33 | -- | 11.42 | -0.9729 | 12.72 | -1.17 | 54.38 | 52.30 | 17.04 | -1.55 | 4.98 | 3.53 | 0.1948 | -- | -13.43 | 5.71 | -102.21 | -- | -3.56 | -- |
| Avicanna Inc | 22.07m | -7.25m | 42.94m | 38.00 | -- | -- | -- | 1.95 | -0.0808 | -0.0808 | 0.2477 | -0.0055 | 1.12 | 3.07 | 12.26 | 580,708.40 | -36.83 | -67.17 | -282.36 | -167.73 | 47.29 | 46.36 | -32.86 | -368.82 | 0.3163 | -10.44 | 0.1834 | -- | 314.82 | 169.57 | 40.67 | -- | -32.29 | -- |
